Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis

Gillian Elizabeth Mead, Catriona Graham, Laurent Billot, Per Näsman, Erik Lundström, Steff Lewis, Graeme J Hankey, Maree L Hackett, John Forbes, Martin Dennis, FOCUS, AFFINITY and EFFECTS trialists, Gillian Elizabeth Mead, Catriona Graham, Laurent Billot, Per Näsman, Erik Lundström, Steff Lewis, Graeme J Hankey, Maree L Hackett, John Forbes, Martin Dennis, FOCUS, AFFINITY and EFFECTS trialists

Abstract

Background: Three large trials of fluoxetine for stroke recovery (FOCUS (fluoxetine or control under supervision), AFFINITY (the Assessment oF FluoxetINe In sTroke recovery) and EFFECTS (Efficacy oF Fluoxetine-a randomisEd Controlled Trial in Stroke)) have been collaboratively designed with the same basic protocol to facilitate an individual patient data analysis (IPDM). The statistical analysis plan for the three individual trials has already been reported in Trials, including a brief description of the IPDM. In this protocol, we describe in detail how we will perform the IPDM.

Methods/design: Data from EFFECTS and AFFINITY will be transferred securely to the FOCUS statistician, who will perform a one-stage IPDM and a two-stage IPDM. For the one-stage IPDM, data will be combined into a single data set and the same analyses performed as described for the individual trials. For the two-stage IPDM, the results for the three individual trials will be combined using fixed effects meta-analyses. The primary and secondary outcome domains for the IPDM are the same as for individual trials. We will also perform analyses according to several subgroups including country of recruitment, ethnicity and trial. We will also explore the effects of fluoxetine on our primary and secondary outcomes in subgroups defined by combinations of characteristics. We also describe additional research questions that will be addressed using the combined data set, and published subsequently, including predictors of important post-stroke problems such as seizures, low mood and bone fractures.

Discussion: An IPDM of our three large trials of fluoxetine for stroke recovery will allow us to provide the most precise estimates of any risks and benefits of fluoxetine vs placebo, to detect reliably a smaller overall effect size than those detectable by the individual trials, to better determine the effects of fluoxetine vs placebo in subgroups of patients and outcomes and to broaden the generalisability of the results. Also, we may identify differences in treatment effects between studies.

Trial registration: FOCUS: ISRCTN ISRCTN83290762 . Registered on 23 May 2012. EudraCT 2011-005616-29 . Registered on 3 February 2012.

Affinity: Australian New Zealand Clinical Trials Registry ACTRN12611000774921 . Registered on 22 July 2011.

Effects: ISRCTN ISRCTN13020412 . Registered on 19 December 2014. ClinicalTrials.gov NCT02683213 . Registered on 2 February 2016. EudraCT 2011-006130-16 . Registered on 8 August 2014.

Keywords: AFFINITY; EFFECTS; FOCUS; Individual patient data meta-analysis; Recovery; Stroke.

Conflict of interest statement

None of the authors declares any financial competing interests relating to this research other than the chief investigators of these three trials having received grant funding to support the trials (see Funding). None of the authors has any non-financial competing interests.

References

    1. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. Bull World Health Organ. 2016;94:634–634A. doi: 10.2471/BLT.16.181636.
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. doi: 10.1016/S0140-6736(16)31678-6.
    1. Chollet F, Tardy J, Albucher J-F, Thalamas E, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123–130. doi: 10.1016/S1474-4422(10)70314-8.
    1. Mead G, Hackett ML, Lundstrom E, Murray V, Hankey GJ, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials. 2015;16(1):369. doi: 10.1186/s13063-015-0864-1.
    1. FOCUS trial collaboration Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393:265–274. doi: 10.1016/S0140-6736(18)32823-X.
    1. AFFINITY trial collaboration Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:651–660. doi: 10.1016/S1474-4422(20)30207-6.
    1. EFFECTS trial collaboration Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:661–669. doi: 10.1016/S1474-4422(20)30219-2.
    1. Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286. doi: 10.1002/14651858.CD009286.pub2.
    1. Marquez-Romero JM, Arauz A, Ruiz-Sandoval JL, Cruz-Estrada Ede L, Huerta-Franco MR, Aguayo-Leytte G, Ruiz-Franco A, Silos H. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials. 2013;14:77. doi: 10.1186/1745-6215-14-77.
    1. Mead GE, Legg L, Tilney R, Hsieh CF, Wu S, Lundström E, Rudbert AS, Kutlubaev M, Dennis MS, Soleimani B, Barugh A, Hackett ML, Hankey GJ. Fluoxetine for stroke recovery: meta-analysis of randomised controlled trials. Int J Stroke. 2019. 10.1177/1747493019879655.
    1. Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2019;(Issue 11):CD009286. 10.1002/14651858.CD009286.pub3.
    1. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. doi: 10.1136/bmj.c221.
    1. Graham C, Lewis S, Forbes J, Mead G, Hackett ML, Hankey GJ, Gommans J, Nguyen HT, Lundström E, Isaksson E, Näsman P, Rudberg AS, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials. 2017;18(1):627. doi: 10.1186/s13063-017-2385-6.
    1. Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci U S A. 2016;113(27):7353–7360. doi: 10.1073/pnas.1510489113.
    1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
    1. Tierney JF, Vale C, Riley R, Catrin TS, Stewart L, Clarke M, Rovers M. Individual participant data (IPDM) meta-analyses of randomised controlled trials: guidance on their use. PLoS Med. 2015;12(7):e1001855. doi: 10.1371/journal.pmed.1001855.
    1. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(162). 10.1186/s12874-017-0442-1.
    1. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias) J Clin Epidemiol. 2011;64(4):407–415. doi: 10.1016/j.jclinepi.2010.07.017.
    1. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPDM statement. JAMA. 2015;313(16):1657–1665. doi: 10.1001/jama.2015.3656.
    1. McDermid I, Barber M, Dennis M, Langhorne P, Macleod MJ, McAlpine CH, Quinn TJ. Home-time is a feasible and valid stroke outcome measure in national datasets originally. Stroke. 2019;50:1282–1285. doi: 10.1161/STROKEAHA.118.023916.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel